SCHEMBL24429433

SCHEMBL24429433

Cc1ccc(Cl)c(S(=O)(=O)NC(C)(C)C)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
POLB P06746 3/20 0.46
HSD17B10 Q99714 1/20 0.46
LMNA P02545 5/20 0.44
GLA P06280 1/20 0.44
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
KDM4E B2RXH2 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
THRB P10828 1/20 0.43
RECQL P46063 1/20 0.43
FBP1 P09467 2/20 0.43
MCL1 Q07820 2/20 0.43
MAPT P10636 2/20 0.42
NPC1 O15118 1/20 0.42
HPGD P15428 1/20 0.42
RAB9A P51151 1/20 0.42
MAPK1 P28482 1/20 0.41
PTGES2 Q9H7Z7 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16261201 0.86 ALDH1A1 (0.46) ALDH1A1POLBLMNAMEN1KMT2A
SCHEMBL22648438 0.84 MCL1 (0.59) ALDH1A1POLBHSD17B10MEN1KMT2A
SCHEMBL28681130 0.81 ALDH1A1 (0.54) ALDH1A1POLBLMNAMEN1KMT2A
SCHEMBL13855836 0.81 GSTO1 (0.53) ALDH1A1L3MBTL1POLBHSD17B10LMNA
SCHEMBL12932911 0.81 ALDH1A1 (0.47) ALDH1A1POLBLMNAGLAMEN1
SCHEMBL17507368 0.81 MEN1 (0.54) ALDH1A1POLBHSD17B10LMNAMEN1
SCHEMBL16377391 0.79 ALDH1A1 (0.46) ALDH1A1POLBLMNAMEN1KMT2A
SCHEMBL7600544 0.79 ALDH1A1 (0.46) ALDH1A1L3MBTL1POLBLMNAMEN1
SCHEMBL24429352 0.78 LMNA (0.43) ALDH1A1L3MBTL1POLBLMNAGLA
SCHEMBL24429434 0.78 ALDH1A1 (0.48) ALDH1A1L3MBTL1POLBLMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220194945-A1 Imidazolopyridine Compounds For IRE1 Inhibition Optikira, LLC 2022-06-23 US disclosed
US-20220153734-A1 Pyrazolopyridine Compounds For IRE1 Inhibition Optikira, LLC 2022-05-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220194945-A1 Imidazolopyridine Compounds For IRE1 Inhibition XBP1, ERN2, ERN1 ALDH1A1 2541/4885L3MBTL1 1472/4885POLB 3535/4885
US-20220153734-A1 Pyrazolopyridine Compounds For IRE1 Inhibition XBP1, ERN1, ERN2 ALDH1A1 2438/4885L3MBTL1 1663/4885POLB 3330/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.